Letairis may prevent PAH linked to scleroderma: Study
Long-term treatment with Volibris (ambrisentan), marketed as Letairis in the U.S., may help prevent mild pulmonary vascular disease from developing into pulmonary arterial hypertension (PAH) in people with scleroderma, a study suggested. “Early treatment and close follow-up could be beneficial in this high-risk group,” wrote the researchers…